On February 11, 2025 BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, reported a collaboration with BeiGene Ltd., a global oncology company that intends to change its name to BeOne Medicines Ltd (Press release, BostonGene, FEB 11, 2025, View Source [SID1234650184]). The collaboration centers on identifying tumor-based biomarkers associated with response and resistance in Mantle Cell Lymphoma (MCL).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This initiative seeks to explain the molecular drivers of therapeutic response and resistance in MCL, a rare and aggressive subtype of B-cell lymphoma, which presents unique challenges due to its high relapse rates and frequent resistance to conventional therapies. By analyzing tumor-specific genomic alterations, immune microenvironment dynamics and clinical outcomes, the collaboration aims to generate actionable insights that can guide precision medicine approaches.
BostonGene will utilize its multi-scale, multi-modal foundation AI platform, integrating next-generation techniques such as whole-exome and RNA sequencing and targeted high-depth hematological cancer panel, to generate comprehensive genomic, transcriptomic, and immunological clinical profiles. The study aims to identify predictive and prognostic biomarker signatures for therapeutic response and disease progression, informing future treatment strategies in MCL.
"At BostonGene, we are dedicated to unraveling the complexity of hematologic malignancies through data-driven molecular and clinical analysis," said Nathan Fowler, MD, Chief Medical Officer at BostonGene. "Our work with BeiGene will facilitate the identification of clinically actionable biomarkers, with the goal of advancing personalized therapeutic approaches and improving outcomes for MCL patients."